Melanie Lohrberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Melanie Lohrberg has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Raphael Koch
Department of Hematology and Medical Oncology, University Medical Center Göttingen (UMG), Göttingen, Germany
3 shared publications Aleksandr Ianevski
Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Helsinki, Finland
2 shared publicationsAnnika Dechow
Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital Cologne, University of Cologne, Cologne, Germany
2 shared publicationsGabriela Salinas
NGS Integrative Genomics Core Unit, University Medical Center Göttingen, Göttingen, Germany
2 shared publicationsGerald Wulf
Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany
2 shared publicationsHolger Bastians
11Department of Molecular Oncology, Section for Cellular Oncology, University Medical Center Göttingen, Göttingen, Germany
2 shared publications
Latest Publications
- Open Access
- 4 December 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1)
Proteasome inhibition as a potential therapeutic target in thymic cancer
Multimodal radio-chemotherapy is the mainstay of treatment for unresectable thymoma (TH) and thymic carcinoma (TC), but there is an urgent need for other therapeutic strategies in these rare tumors. The epithelial cells of the normal thymus express the three major proteasome classes: constitutive, immunoproteasome, and thymoproteasome, making thymic epithelial tumors potential candidates for treatment with proteasome inhibitors. In a drug screen of 120 cytotoxic agents, the two thymic carcinoma cell lines 1889c and MP57 showed exquisite sensitivity to the proteasome inhibitor carfilzomib (PR-171). Immunohistochemistry, gene expression, and in vitro functional studies were used in a comprehensive sample collection to investigate the correlation between immunoproteasome subunit expression and response to carfilzomib. 50% of TC and a substantial proportion of TH strongly expressed immunoproteasome subunits and showed functional activity of β1i (PSMB9), β2i (PSMB10), and β5i (PSMB8). INF-γ treatment induced immunoproteasome expression and increased cell sensitivity to carfilzomib, while siRNA knockdown reduced carfilzomib response in vitro. Carfilzomib synergized with BCL2 family protein inhibitors (navitoclax or AZD5991), suggesting that drug combinations could be used to reduce the dose of each drug to minimize toxicity. Notably, thymic carcinomas differed from squamous cell carcinomas in other organs by higher levels of β5i (PSMB8) and constitutive proteasome β5 (PSMB5). We hypothesize that TC (and probably many TH) are uniquely suited for treatment with proteasome inhibitors alone or in combination with selective BH3 mimetics.
- 4 December 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1)
Open AccessProteasome inhibition as a potential therapeutic target in thymic cancer
Multimodal radio-chemotherapy is the mainstay of treatment for unresectable thymoma (TH) and thymic carcinoma (TC), but there is an urgent need for other therapeutic strategies in these rare tumors. The epithelial cells of the normal thymus express the three major proteasome classes: constitutive, immunoproteasome, and thymoproteasome, making thymic epithelial tumors potential candidates for treatment with proteasome inhibitors. In a drug screen of 120 cytotoxic agents, the two thymic carcinoma cell lines 1889c and MP57 showed exquisite sensitivity to the proteasome inhibitor carfilzomib (PR-171). Immunohistochemistry, gene expression, and in vitro functional studies were used in a comprehensive sample collection to investigate the correlation between immunoproteasome subunit expression and response to carfilzomib. 50% of TC and a substantial proportion of TH strongly expressed immunoproteasome subunits and showed functional activity of β1i (PSMB9), β2i (PSMB10), and β5i (PSMB8). INF-γ treatment induced immunoproteasome expression and increased cell sensitivity to carfilzomib, while siRNA knockdown reduced carfilzomib response in vitro. Carfilzomib synergized with BCL2 family protein inhibitors (navitoclax or AZD5991), suggesting that drug combinations could be used to reduce the dose of each drug to minimize toxicity. Notably, thymic carcinomas differed from squamous cell carcinomas in other organs by higher levels of β5i (PSMB8) and constitutive proteasome β5 (PSMB5). We hypothesize that TC (and probably many TH) are uniquely suited for treatment with proteasome inhibitors alone or in combination with selective BH3 mimetics.
- Open Access
- 17 October 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (20) , 5327-5340
Discovery of molecularly-informed therapeutic strategies for mature T-cell leukemias and lymphomas
Mature T-cell leukemias and lymphomas (mTCL) comprise a clinically and genetically heterogeneous group of lymphoid malignancies. Most subtypes of peripheral T-cell lymphomas and leukemic T-cell malignancies show an aggressive clinical course and poor prognosis. Thus, these diseases urgently require novel therapeutic strategies. Taking advantage of recent progress deciphering the genetic basis of mTCL, we generated a comprehensive database of genetic alterations from 1825 patients with mTCL and utilized bioinformatic methodology developed to support treatment decisions in molecular tumor boards to identify novel potential therapeutics. Based on the results of this approach, we performed a systematic in vitro drug screen in molecularly characterized cell lines of mTCL to assess the activity of potential therapeutics. Of these, the cell cycle regulator WEE1 stood out as a novel therapeutic target in a genetically defined subgroup of mTCL. Indeed, WEE1 kinase inhibitors potently induced replication stress, premature mitotic entry, accumulation of DNA damage and induction of apoptosis in mTCL cell lines. Building on the single-agent activity of clinical grade WEE1 inhibitors, we next explored potential drug combination strategies through mechanistic studies. With this, we identified strong synergistic effects of combined WEE1 and JAK inhibition in genetically defined subtypes of mTCL, including primary patient samples of T-cell prolymphocytic leukemia. In summary, our study provides a comprehensive overview of the genetic landscape in mTCL and potential therapeutics in genetically defined subtypes. As such, we identified synergistic effects of dual WEE1 and JAK inhibition in cases with altered JAK/STAT signaling as a blueprint for clinical testing.
- 17 October 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 9 (20) , 5327-5340
Open AccessDiscovery of molecularly-informed therapeutic strategies for mature T-cell leukemias and lymphomas
Mature T-cell leukemias and lymphomas (mTCL) comprise a clinically and genetically heterogeneous group of lymphoid malignancies. Most subtypes of peripheral T-cell lymphomas and leukemic T-cell malignancies show an aggressive clinical course and poor prognosis. Thus, these diseases urgently require novel therapeutic strategies. Taking advantage of recent progress deciphering the genetic basis of mTCL, we generated a comprehensive database of genetic alterations from 1825 patients with mTCL and utilized bioinformatic methodology developed to support treatment decisions in molecular tumor boards to identify novel potential therapeutics. Based on the results of this approach, we performed a systematic in vitro drug screen in molecularly characterized cell lines of mTCL to assess the activity of potential therapeutics. Of these, the cell cycle regulator WEE1 stood out as a novel therapeutic target in a genetically defined subgroup of mTCL. Indeed, WEE1 kinase inhibitors potently induced replication stress, premature mitotic entry, accumulation of DNA damage and induction of apoptosis in mTCL cell lines. Building on the single-agent activity of clinical grade WEE1 inhibitors, we next explored potential drug combination strategies through mechanistic studies. With this, we identified strong synergistic effects of combined WEE1 and JAK inhibition in genetically defined subtypes of mTCL, including primary patient samples of T-cell prolymphocytic leukemia. In summary, our study provides a comprehensive overview of the genetic landscape in mTCL and potential therapeutics in genetically defined subtypes. As such, we identified synergistic effects of dual WEE1 and JAK inhibition in cases with altered JAK/STAT signaling as a blueprint for clinical testing.
- Open Access
- 31 March 2025
- Published by Wiley in European Journal of Haematology
- Vol. 115 (1) , 82-95
Dual Targeting of Pim and PI3 Kinases in Mature T‐Cell Lymphoma
Provirus Integration site for Moloney leukemia virus (Pim) family members are well‐known oncogenes, with an expression that is restricted to few cell types including hematopoietic cells in adult organisms, making it a promising target for lymphoma treatment. Indeed, previous studies in mature T‐cell lymphoma (mTCL) cells revealed frequent upregulation of Pim expression. Nevertheless, inhibition of Pim kinases showed only minor effects on the viability of mTCL cells so far. Thus, we here addressed cellular responses to therapeutic inhibition of Pim kinases and identified a PI3K/Akt‐driven activation of mTOR as a significant escape mechanism mitigating the anti‐lymphoma effects of Pim inhibition. Indeed, dual inhibition of Pim and PI3 kinases showed synergistic anti‐lymphoma effects in vitro through downregulation of mTOR‐induced protein translation and mitigation of BCL‐xL‐mediated anti‐apoptotic mechanisms. Based on this finding, we next explored the therapeutic potential of the dual Pim/PI3K inhibitor IBL‐202 in mTCL cell lines. Strikingly, IBL‐202 strongly induced cell‐cycle‐dependent cell death in cell lines of different mTCL subtypes. Together, our study provides mechanistic evidence supporting a therapeutic strategy of dual Pim‐ and PI3‐kinase inhibition in mature T‐cell lymphoma.
- 31 March 2025
- Published by Wiley in European Journal of Haematology
- Vol. 115 (1) , 82-95
Open AccessDual Targeting of Pim and PI3 Kinases in Mature T‐Cell Lymphoma
Provirus Integration site for Moloney leukemia virus (Pim) family members are well‐known oncogenes, with an expression that is restricted to few cell types including hematopoietic cells in adult organisms, making it a promising target for lymphoma treatment. Indeed, previous studies in mature T‐cell lymphoma (mTCL) cells revealed frequent upregulation of Pim expression. Nevertheless, inhibition of Pim kinases showed only minor effects on the viability of mTCL cells so far. Thus, we here addressed cellular responses to therapeutic inhibition of Pim kinases and identified a PI3K/Akt‐driven activation of mTOR as a significant escape mechanism mitigating the anti‐lymphoma effects of Pim inhibition. Indeed, dual inhibition of Pim and PI3 kinases showed synergistic anti‐lymphoma effects in vitro through downregulation of mTOR‐induced protein translation and mitigation of BCL‐xL‐mediated anti‐apoptotic mechanisms. Based on this finding, we next explored the therapeutic potential of the dual Pim/PI3K inhibitor IBL‐202 in mTCL cell lines. Strikingly, IBL‐202 strongly induced cell‐cycle‐dependent cell death in cell lines of different mTCL subtypes. Together, our study provides mechanistic evidence supporting a therapeutic strategy of dual Pim‐ and PI3‐kinase inhibition in mature T‐cell lymphoma.
- Open Access
- 13 June 2024
- Published by Springer Nature in Research Square
Discovery of molecularly-informed therapeutic strategies for mature T-cell neoplasms
Mature T-cell lymphomas and leukemias (mTCL) comprise a clinically and genetically heterogeneous group of lymphoid malignancies. Most subtypes of peripheral T-cell lymphomas and leukemic T-cell malignancies show an aggressive clinical course and poor prognosis. Thus, these diseases urgently require novel therapeutic strategies. Taking advantage of recent progress deciphering the genetic basis of mTCL, we generated a comprehensive database of genetic alterations from >1 800 patients with mTCL and utilized bioinformatic methodology developed to support treatment decisions in molecular tumorboards to identify novel potential therapeutics. To assess the in vitro activity of potential therapeutics, broad drug screening was performed in molecularly characterized cell lines of mTCL. Notably, the cell cycle regulator WEE1 was identified as a novel therapeutic target in mTCL. Indeed, WEE1 kinase inhibitors potently induced replication stress, premature mitotic entry, accumulation of DNA damage and induction of apoptosis in mTCL cell lines. Exploring potential drug combination strategies through mechanistic studies, we identified strong synergistic effects of combined WEE1 and JAK inhibition in JAK/STAT driven preclinical models as well as in primary patient samples of T-cell prolymphocytic leukemia (T-PLL). In summary, our results identified combinatorial effects of WEE1 and JAK inhibition in genetically defined subtypes of mTCL.
- 13 June 2024
- Published by Springer Nature in Research Square
Open AccessDiscovery of molecularly-informed therapeutic strategies for mature T-cell neoplasms
Mature T-cell lymphomas and leukemias (mTCL) comprise a clinically and genetically heterogeneous group of lymphoid malignancies. Most subtypes of peripheral T-cell lymphomas and leukemic T-cell malignancies show an aggressive clinical course and poor prognosis. Thus, these diseases urgently require novel therapeutic strategies. Taking advantage of recent progress deciphering the genetic basis of mTCL, we generated a comprehensive database of genetic alterations from >1 800 patients with mTCL and utilized bioinformatic methodology developed to support treatment decisions in molecular tumorboards to identify novel potential therapeutics. To assess the in vitro activity of potential therapeutics, broad drug screening was performed in molecularly characterized cell lines of mTCL. Notably, the cell cycle regulator WEE1 was identified as a novel therapeutic target in mTCL. Indeed, WEE1 kinase inhibitors potently induced replication stress, premature mitotic entry, accumulation of DNA damage and induction of apoptosis in mTCL cell lines. Exploring potential drug combination strategies through mechanistic studies, we identified strong synergistic effects of combined WEE1 and JAK inhibition in JAK/STAT driven preclinical models as well as in primary patient samples of T-cell prolymphocytic leukemia (T-PLL). In summary, our results identified combinatorial effects of WEE1 and JAK inhibition in genetically defined subtypes of mTCL.
- Open Access
- 25 January 2018
- Published by Springer Nature in BMC Immunology
- Vol. 19 (1) , 5
Co-localization of lymphoid aggregates and lymphatic networks in nose- (NALT) and lacrimal duct-associated lymphoid tissue (LDALT) of mice
The lymphatic vascular pattern in the head of mice has rarely been studied, due to problems of sectioning and immunostaining of complex bony structures. Therefore, the association of head lymphoid tissues with the lymphatics has remained unknown although the mouse is the most often used species in immunology. Here, we studied the association of nasal and nasolacrimal duct lymphatics with lymphoid aggregates in 14-day-old and 2-month-old mice. We performed paraffin sectioning of whole, decalcified heads, and immunostaining with the lymphatic endothelial cell-specific antibodies Lyve-1 and Podoplanin. Most parts of the nasal mucous membrane do not contain any lymphatics. Only the region of the inferior turbinates contains lymphatic networks, which are connected to those of the palatine. Nose-associated lymphoid tissue (NALT) is restricted to the basal parts of the nose, which contain lymphatics. NALT is continued occipitally and can be found at both sides along the sphenoidal sinus, again in close association with lymphatic networks. Nasal lymphatics are connected to those of the ocular region via a lymphatic network along the nasolacrimal duct (NLD). By this means, lacrimal duct-associated lymphoid tissue (LDALT) has a dense supply with lymphatics. NALT and LDALT play a key role in the immune system of the mouse head, where they function as primary recognition sites for antigens. Using the dense lymphatic networks along the NLD described in this study, these antigens reach lymphatics near the palatine and are further drained to lymph nodes of the head and neck region. NALT and LDALT develop in immediate vicinity of lymphatic vessels. Therefore, we suggest a causative connection of lymphatic vessels and the development of lymphoid tissues.
- 25 January 2018
- Published by Springer Nature in BMC Immunology
- Vol. 19 (1) , 5
Open AccessCo-localization of lymphoid aggregates and lymphatic networks in nose- (NALT) and lacrimal duct-associated lymphoid tissue (LDALT) of mice
The lymphatic vascular pattern in the head of mice has rarely been studied, due to problems of sectioning and immunostaining of complex bony structures. Therefore, the association of head lymphoid tissues with the lymphatics has remained unknown although the mouse is the most often used species in immunology. Here, we studied the association of nasal and nasolacrimal duct lymphatics with lymphoid aggregates in 14-day-old and 2-month-old mice. We performed paraffin sectioning of whole, decalcified heads, and immunostaining with the lymphatic endothelial cell-specific antibodies Lyve-1 and Podoplanin. Most parts of the nasal mucous membrane do not contain any lymphatics. Only the region of the inferior turbinates contains lymphatic networks, which are connected to those of the palatine. Nose-associated lymphoid tissue (NALT) is restricted to the basal parts of the nose, which contain lymphatics. NALT is continued occipitally and can be found at both sides along the sphenoidal sinus, again in close association with lymphatic networks. Nasal lymphatics are connected to those of the ocular region via a lymphatic network along the nasolacrimal duct (NLD). By this means, lacrimal duct-associated lymphoid tissue (LDALT) has a dense supply with lymphatics. NALT and LDALT play a key role in the immune system of the mouse head, where they function as primary recognition sites for antigens. Using the dense lymphatic networks along the NLD described in this study, these antigens reach lymphatics near the palatine and are further drained to lymph nodes of the head and neck region. NALT and LDALT develop in immediate vicinity of lymphatic vessels. Therefore, we suggest a causative connection of lymphatic vessels and the development of lymphoid tissues.
- Open Access
- 6 September 2016
- Published by Springer Nature in Cell and tissue research
- Vol. 366 (3) , 667-677
The lymphatic vascular system of the mouse head
Histological studies of the lymphatic vascular system in adult mice are hampered because bones cannot be sectioned properly. Here, we decalcified the heads of 14-day-old mice, embedded them in paraffin and stained resultant serial sections with the lymphendothelial-specific antibodies Lyve-1 and Podoplanin. We show that the tissues with the highest lymphatic vascular density are the dermis and the oral mucous membranes. In contrast, the nasal mucous membrane is devoid of lymphatics, except for its most basal parts below the vomeronasal organ. The inferior nasal turbinate contains numerous lymphatics and is connected to the nasolacrimal duct (NLD), which is ensheathed by a dense network of lymphatics. The lymphatics of the eye lids and conjunctiva are connected to those of the inferior nasal turbinate. We suggest that cerebro-spinal fluid (CSF) can drain via the optic nerve and NLD lymphatics, whereas CSF drained via the Fila olfactoria into the nasal mucous membrane is used for moisturization of the respiratory air. Tongue, palatine and buccal mucous membranes possess numerous lymphatics, whereas the dental pulp has none. Lymphatics are present in the maxillary gland and close to the temporomandibular joint, suggesting the augmentation of lymph flow by chewing and yawning. Lymphatics can also be found in the dura mater and in the dural septae entering into deeper parts of the brain. Our findings are discussed with regard to CSF drainage and potential routes for ocular tumor dissemination.
- 6 September 2016
- Published by Springer Nature in Cell and tissue research
- Vol. 366 (3) , 667-677
Open AccessThe lymphatic vascular system of the mouse head
Histological studies of the lymphatic vascular system in adult mice are hampered because bones cannot be sectioned properly. Here, we decalcified the heads of 14-day-old mice, embedded them in paraffin and stained resultant serial sections with the lymphendothelial-specific antibodies Lyve-1 and Podoplanin. We show that the tissues with the highest lymphatic vascular density are the dermis and the oral mucous membranes. In contrast, the nasal mucous membrane is devoid of lymphatics, except for its most basal parts below the vomeronasal organ. The inferior nasal turbinate contains numerous lymphatics and is connected to the nasolacrimal duct (NLD), which is ensheathed by a dense network of lymphatics. The lymphatics of the eye lids and conjunctiva are connected to those of the inferior nasal turbinate. We suggest that cerebro-spinal fluid (CSF) can drain via the optic nerve and NLD lymphatics, whereas CSF drained via the Fila olfactoria into the nasal mucous membrane is used for moisturization of the respiratory air. Tongue, palatine and buccal mucous membranes possess numerous lymphatics, whereas the dental pulp has none. Lymphatics are present in the maxillary gland and close to the temporomandibular joint, suggesting the augmentation of lymph flow by chewing and yawning. Lymphatics can also be found in the dura mater and in the dural septae entering into deeper parts of the brain. Our findings are discussed with regard to CSF drainage and potential routes for ocular tumor dissemination.